Inteliphage

Executive Summary

Inteliphage is a Belgian biotechnology company founded in 2019 and headquartered in Ghent, with a mission to combat antimicrobial resistance (AMR) through personalized bacteriophage (phage) therapy. The company has developed an integrated platform that combines diagnostics, a curated phage library, and clinical support tools to enable healthcare professionals to treat difficult-to-treat bacterial infections when antibiotics fail. By leveraging a precision medicine approach, Inteliphage aims to address the growing global threat of AMR, which is responsible for hundreds of thousands of deaths annually. The platform is designed to rapidly identify effective phages against specific bacterial strains, thereby offering a tailored therapeutic option for patients with limited alternatives. Inteliphage operates in the biologics sector and is still in an early stage, with no disclosed financing rounds or valuation. The company's technology holds significant promise given the urgent need for novel antimicrobial strategies, but it faces typical early-stage challenges including regulatory hurdles, clinical validation, and scalability. The personalized nature of phage therapy creates complexity in manufacturing and distribution, yet also provides a competitive advantage over traditional broad-spectrum antibiotics. With the AMR market expected to grow substantially, Inteliphage is well-positioned to attract partnerships and funding to advance its platform. Near-term success hinges on raising capital and securing clinical partnerships to validate its personalized therapy model.

Upcoming Catalysts (preview)

• Q3 2026Series A financing round70% success
• Q4 2026Partnership with a major hospital network for phage therapy clinical access50% success